Article Text
PDF
Abstract
Amantadine is an N-methyl-d-aspartate receptor antagonist with secondary dopaminergic activity that is used to treat Parkinson’s disease-related dyskinesia and to treat fatigue in multiple sclerosis. It is primarily renally excreted and so impaired kidney function prolongs its half-life and may lead to toxicity. We describe a woman with multiple sclerosis taking amantadine who developed acute renal impairment, which triggered florid visual hallucinations that resolved on stopping the medication.
- multiple sclerosis
- hallucinations
Data availability statement
No data are available.
Statistics from Altmetric.com
Data availability statement
No data are available.
Footnotes
Contributors Both authors were involved in the clinical care of the patient described in the case report, the reading and the final approval of the manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned. Externally peer reviewed by Freddie Vonberg, London, UK, and Gillian Ingram, Swansea, UK.
Linked Articles
Read the full text or download the PDF:
Other content recommended for you
- Change in disability in patients with multiple sclerosis: a 20-year prospective population-based analysis
- Contemporary study of multiple sclerosis disability in South East Wales
- How common is truly benign MS in a UK population?
- Brain atrophy and lesion load predict long term disability in multiple sclerosis
- Factors associated with and long-term outcome of benign multiple sclerosis: a nationwide cohort study
- The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry
- Spinal cord lesions and brain grey matter atrophy independently predict clinical worsening in definite multiple sclerosis: a 5-year, multicentre study
- Amantadine and/or transcranial magnetic stimulation for fatigue associated with multiple sclerosis (FETEM): study protocol for a phase 3 randomised, double-blind, cross-over, controlled clinical trial
- The patient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical)
- UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model